On April 16, a delegation from Enterprise Singapore's China Directorate, led by Lin Weiyin, Deputy Director, and Ma Haiyang, Deputy Section Head, visited Shenzhen Cell Valley for site inspections and exchanges. The discussions focused on the company's progress in cell and gene therapy, clinical translation of emerging biomedical technologies, and its one-stop CRO/CDMO services.

During the visit, Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley, along with Fu Yuchen, Assistant to the Chairman, and Han Shu, Director of the General Administration Office, welcomed the delegation. They accompanied the guests on a tour of the company's exhibition hall, R&D facilities, and production platforms, followed by in-depth exchanges on trends in cell therapy, technological innovation, clinical translation, and cross-border collaboration.

During the discussion, Shi Yuanyuan noted that the company is actively advancing its international strategy, with a strong focus on Singapore's unique advantages in biomedicine, healthcare, and global innovation collaboration, as well as a keen interest in entering the Singaporean and broader Southeast Asian markets. Looking ahead, Shenzhen Cell Valley aims to leverage Singapore as a strategic hub, drawing on its comprehensive capabilities in cell and gene therapy technology platforms, product manufacturing, clinical translation, and compliance services, to actively explore cooperation opportunities across Southeast Asia and accelerate its global business expansion.

The Enterprise Singapore delegation acknowledged Shenzhen Cell Valley's achievements in platform development, industrialization, and international outreach. The visit deepened mutual understanding and laid a solid foundation for future collaboration on cell therapy and biomedicine.